Cipla Supply Partner’s Greece Facility Gets OAI Classification from US FDA

Market Closed – NSE India S.E.			5-day change	1st Jan Change
1,326.50 ^INR	-1.09%		-2.20%	-12.23%

Published on 02/23/2026
at 05:10 am EST

MT Newswires

05:10am	Cipla Supply Partner’s Greece Facility Gets OAI Classification from US FDA	MT
Feb. 20	LIC raises stake in Cipla to 9.091% from 7.055% between Nov and Feb – filing	RE
Feb. 17	Lilly targets India as global export hub amid booming Mounjaro sales, executive says	RE
Feb. 13	Biocon aims for revenue surge with rollout of generic weight-loss drugs	RE
Feb. 10	Cipla says USFDA inspection at Invagen manufacturing facility in Hauppauge, Long Island, New York, USA	RE
Feb. 09	Cipla Arm’s New York Unit Gets Two Observations in US FDA Inspection	MT
Feb. 09	India’s Aurobindo Pharma posts higher profit on steady domestic demand	RE
Feb. 05	Cipla says tax department initiates inspection at Cipla facilities	RE
Feb. 05	Drugmaker Alembic Pharma posts earnings dip on Indian labour code changes	RE
Feb. 02	Cipla Names Global Chief People Officer	MT
Feb. 01	Cipla Limited Appoints Arun Kakatkar as Global Chief People Officer and Senior Management Personnel, Effective March 17, 2026	CI
Jan. 27	Nomura Adjusts Cipla’s Price Target to INR1,510 From INR1,770, Keeps at Buy	MT
Jan. 26	Jefferies Downgrades Cipla to Underperform From Hold, Adjusts Price Target to INR1,170 From INR1,630	MT
Jan. 23	Cipla Limited, Q3 2026 Earnings Call, Jan 23, 2026
Jan. 23	India Stocks Close Week with Losses Amid Foreign Outflows, Weak Earnings	MT

Duration

Period

Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products.

Net sales by source of income break down between sale of products (96.9%) and services (3.1%).

Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).